NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
- Conditions
- Recurrent Rhabdoid TumorRefractory Epithelioid SarcomaRefractory Kidney Medullary CarcinomaRefractory Malignant Solid NeoplasmEpithelioid SarcomaMalignant Solid NeoplasmKidney Medullary CarcinomaRecurrent Epithelioid SarcomaRecurrent Malignant Solid NeoplasmRefractory Atypical Teratoid/Rhabdoid Tumor
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyOther: Fludeoxyglucose F-18Procedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: X-Ray Imaging
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT05286801
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸UCSF Medical Center-Mission Bay, San Francisco, California, United States
🇺🇸Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
- Conditions
- Ovarian High Grade Serous AdenocarcinomaUnresectable Fallopian Tube High Grade Serous AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaPrimary Peritoneal Endometrioid AdenocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaStage III Primary Peritoneal Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Unresectable Fallopian Tube Endometrioid AdenocarcinomaUnresectable Ovarian Endometrioid AdenocarcinomaUnresectable Ovarian High Grade Serous Adenocarcinoma
- Interventions
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT05276973
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Women and Infants Hospital, Providence, Rhode Island, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- Conditions
- Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Hodgkin Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Positron Emission Tomography
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT05272384
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
- Conditions
- Endometrial CarcinomaEndometrial Undifferentiated CarcinomaUterine Corpus CarcinosarcomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous Adenocarcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestRadiation: High-Dose-Rate Vaginal Cuff BrachytherapyProcedure: Multigated Acquisition ScanDrug: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabOther: Survey Administration
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 360
- Registration Number
- NCT05256225
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
- Conditions
- Carcinoma, NeuroendocrineNeuroendocrine Tumors
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 300
- Registration Number
- NCT05237934
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial
- Conditions
- Human Papillomavirus-Related Cervical Carcinoma
- Interventions
- Biological: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedOther: Questionnaire AdministrationBiological: Recombinant Human Papillomavirus Bivalent VaccineBiological: Recombinant Human Papillomavirus Nonavalent Vaccine
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5000
- Registration Number
- NCT05237947
- Locations
- 🇨🇷
Agencia Costarricense de Investigaciones Biomédicas (ACIB), Liberia, Guanacaste, Costa Rica
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
- Conditions
- LymphomaLeukemia
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT05237986
- Locations
- 🇺🇸
Children s Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸Seattle Children s Hospital, Seattle, Washington, United States
Testing Obeticholic Acid for Familial Adenomatous Polyposis
- Conditions
- Attenuated Familial Adenomatous PolyposisFamilial Adenomatous PolyposisColorectal CarcinomaDuodenal Carcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Gastrointestinal EndoscopyDrug: Placebo AdministrationOther: Questionnaire Administration
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT05223036
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
- Conditions
- Congenital Heart Disease
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2025-05-01
- Target Recruit Count
- 100
- Registration Number
- NCT05213598
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
- Conditions
- Combined Hepatocellular Carcinoma and CholangiocarcinomaStage III Liver CancerStage IV Liver Cancer
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Conventional Magnetic Resonance Imaging
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT05211323
- Locations
- 🇺🇸
UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny, Iowa, United States
🇺🇸UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines, Iowa, United States
🇺🇸Sutter Auburn Faith Hospital, Auburn, California, United States